The FDA has approved Rasonque, a targeted oral medication for patients with metastatic pancreatic adenocarcinoma who have previously undergone systemic therapy.
Key facts
- •Rasonque is approved for metastatic pancreatic adenocarcinoma patients who have previously received systemic therapy.
- •Phase 3 trial data showed an average survival of 13.2 months with Rasonque versus 6.7 months with chemotherapy.
- •The drug targets RAS mutations, which are responsible for over 90% of pancreatic tumors.
- •Pancreatic cancer was the 12th most common cancer in 2024, with over 530,000 global diagnoses.
- •The annual cost for a full course of Rasonque therapy is reported at nearly $500,000.
On August 26, the U.S. Food and Drug Administration approved Rasonque, also known as daraxonrasib, to treat metastatic pancreatic adenocarcinoma. The approval follows Phase 3 clinical trial results showing that patients receiving the drug experienced an average survival of 13.2 months, compared to 6.7 months for those treated with chemotherapy alone.
By the numbers
Mechanism of Action
Rasonque is designed to target the RAS family of genes, which are present in over 90% of pancreatic adenocarcinoma cases and drive tumor growth by sending uncontrolled signals to cells. The drug functions as a 'molecular glue' that binds to the cellular chaperone protein cyclophilin A. This complex then locks onto the active RAS protein, creating a 'tri-complex' that prevents the protein from interacting with signaling partners, effectively halting tumor growth.
Clinical Application and Considerations
The medication is intended for patients whose cancer has spread beyond the pancreas and who have already received prior systemic therapy, such as chemotherapy. Medical experts note that while the drug offers a more precise alternative to traditional chemotherapy, questions remain regarding its use as a first-line treatment or in patients with resectable tumors. Additionally, the medical community is monitoring for potential drug resistance and the long-term durability of the treatment.
Economic and Safety Profile
Rasonque is administered as a once-daily oral pill. While it is noted for sparing patients from some side effects associated with chemotherapy, clinicians emphasize the need for monitoring and prophylactic treatment for rashes. The drug is priced at approximately $500,000 for a full year of therapy.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by Healthline.
